ATP7A Antibody (D-9): sc-376467

ATP7A Antibody (D-9) is a mouse monoclonal IgG2a kappa light chain antibody that detects ATP7A protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). ATP7A (D-9) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. ATP7A, also known as Copper-transporting ATPase 1, is crucial for maintaining copper homeostasis in the body, functioning as a transmembrane copper-translocating P-type ATPase. ATP7A plays a significant role in systemic copper absorption in the gut and reabsorption in the kidney, which is vital for preventing copper deficiency and toxicity. ATP7A is primarily located in the trans-Golgi network and the basolateral membrane of polarized epithelial cells, such as those found in the kidney and intestine, where ATP7A facilitates the export of excess copper from cells into the bloodstream. While ATP7A is not typically expressed in most normal tissues, ATP7A is found in a significant fraction of various tumor types, where increased expression can confer resistance to chemotherapeutic agents like cisplatin and carboplatin. Mutations in the ATP7A gene are associated with Menkes disease, a severe disorder that leads to fatal outcomes in early childhood, while mutations in the ATP7B gene are linked to Wilson disease, which presents with neurological symptoms and liver damage.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ATP7A Antibody (D-9) References:

1. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.  |  Samimi, G., et al. 2003. Clin Cancer Res. 9: 5853-9. PMID: 14676106
2. The distinct functional properties of the nucleotide-binding domain of ATP7B, the human copper-transporting ATPase: analysis of the Wilson disease mutations E1064A, H1069Q, R1151H, and C1104F.  |  Morgan, CT., et al. 2004. J Biol Chem. 279: 36363-71. PMID: 15205462
3. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.  |  Samimi, G., et al. 2004. Mol Pharmacol. 66: 25-32. PMID: 15213293
4. Signals regulating trafficking of Menkes (MNK; ATP7A) copper-translocating P-type ATPase in polarized MDCK cells.  |  Greenough, M., et al. 2004. Am J Physiol Cell Physiol. 287: C1463-71. PMID: 15269005
5. Copper-dependent protein-protein interactions studied by yeast two-hybrid analysis.  |  van Dongen, EM., et al. 2004. Biochem Biophys Res Commun. 323: 789-95. PMID: 15381069
6. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.  |  Song, IS., et al. 2004. Mol Cancer Ther. 3: 1543-9. PMID: 15634647
7. The copper-transporting ATPases, menkes and wilson disease proteins, have distinct roles in adult and developing cerebellum.  |  Barnes, N., et al. 2005. J Biol Chem. 280: 9640-5. PMID: 15634671
8. ATP7A-related copper transport diseases-emerging concepts and future trends.  |  Kaler, SG. 2011. Nat Rev Neurol. 7: 15-29. PMID: 21221114
9. Small amounts of functional ATP7A protein permit mild phenotype.  |  Møller, LB. 2015. J Trace Elem Med Biol. 31: 173-7. PMID: 25172213
10. ATP7A-Regulated Enzyme Metalation and Trafficking in the Menkes Disease Puzzle.  |  Horn, N. and Wittung-Stafshede, P. 2021. Biomedicines. 9: PMID: 33917579
11. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A.  |  Gao, W., et al. 2021. Mol Oncol. 15: 3527-3544. PMID: 34390123
12. ATP7A-related copper transport disorders: A systematic review and definition of the clinical subtypes.  |  De Feyter, S., et al. 2023. J Inherit Metab Dis. 46: 163-173. PMID: 36692329

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-ATP7A Antibody (D-9) has 20 citations in a variety of scientific publications.

Primary antibodies like Anti-ATP7A Antibody (D-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

ATP7A Antibody (D-9) Specifications

Alternate Product Name: ATP7A

Product Clone Name: D-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 1-180

Epitope Target: ATP7A

Epitope Species: human

Product Reactivity/Detection: ATP7A isoforms 1, 2, 4 and 5

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 20 citations in various scientific publications

Available Conjugates/Forms for ATP7A Antibody (D-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin